Factor H-Binding Peptides for Biomaterial Complement Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomaterials used in medical applications often induce adverse reactions due to activation of the innate immunity and pro-inflammatory pathways, leading to tissue damage, as they rapidly adsorb plasma proteins and trigger complement activation, particularly through the alternative pathway, which is challenging to inhibit with continuous administration of soluble inhibitors.
Innovation Solution
Development of factor H-binding peptides that bind to factor H without interfering with its complement-inhibitory activity, specifically down-regulating the alternative pathway of complement activation by inhibiting the formation of AP C3 convertase, and are immobilized onto biomaterial surfaces to recruit factor H, thereby reducing complement activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biomaterial surfaces are used in medical applications, then they provide structural support and functionality, but they activate complement through the alternative pathway leading to inflammation and tissue damage
Solution Approach 1:
The patent uses factor H-binding peptides as intermediary molecules that bridge the biomaterial surface and factor H. These peptides are immobilized on the biomaterial surface and specifically recruit factor H from plasma, preventing direct complement activation while maintaining regulatory function. The peptide acts as a mediator that translates the biomaterial surface into a complement-regulatory surface without requiring continuous administration of soluble inhibitors.
Solution Approach 2:
The patent applies preliminary action by pre-immobilizing factor H-binding peptides on the biomaterial surface before implantation. This preliminary coating ensures that factor H is recruited and bound to the surface in advance, creating a protective layer that prevents complement activation from the outset. The surface is pre-equipped with the ability to regulate complement before exposure to biological fluids.
2Object-affected harmful factors
If soluble complement inhibitors are administered continuously, then complement activation is inhibited, but the treatment complexity and cost increase
Solution Approach 1:
The patent implements self-service by enabling the biomaterial surface to autonomously regulate complement activation through immobilized factor H-binding peptides. The surface automatically recruits and binds factor H from plasma upon exposure, creating a self-regulating system that does not require external administration of inhibitors. The biomaterial itself provides the complement-regulatory function it needs through the integrated peptide-cofactor system.
3Object-affected harmful factors
If factor H is bound to biomaterial surfaces, then complement activation is inhibited, but the binding may impede the complement-inhibitory activity of factor H
Solution Approach 1:
The patent applies local quality by designing factor H-binding peptides with specific binding characteristics that target particular regions of factor H (such as SCR domains 5-18) without interfering with the regulatory domains (SCR 1-4 and SCR 19-20). This localized binding approach ensures that factor H is recruited to the surface while its complement-regulatory functions remain intact and operational.
Solution Approach 2:
The patent segments the factor H molecule into distinct functional domains, recognizing that different regions perform different functions. The binding peptides target non-regulatory segments of factor H, allowing the regulatory segments to remain functional. This segmentation understanding enables selective binding that preserves overall factor H activity while achieving surface recruitment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The factor H-binding peptides effectively inhibit biomaterial-induced complement activation by recruiting factor H, maintaining its regulatory activity and reducing inflammation, making the biomaterials more biocompatible without the need for continuous soluble inhibitor administration.
Implementation Method 1
factor H-binding peptides that bind to a region of factor H that does not impede the complement-inhibitory activity of factor H
Implementation Method 2
inhibiting the formation of AP C3 convertase
Data Source
Figure 1A~1C
Figure 2A~2B
Figure 3A~3C
AI summary
Factor H-binding peptides that binds to a region of factor H that does not impede the complement-inhibitory activity of factor H are disclosed. When immobilized onto the surface of a biomaterial, these peptides recruit factor H, resulting in a substantial inhibition of biomaterial-induced complement activation in a biological substance exposed to the biomaterial.